2008-03-04 13:21 ET - News Release

Dr. Terrance Owen reports:

ALDA RECEIVES US PATENT NO. 7,338,927 FOR T36 TRADEMARK

Alda Pharmaceuticals Corp. has received, from the United States Patent and Trademark Office, U.S. Patent No. 7,338,927. The patent provides protection for the composition and production methods for Alda's T36 formulation until Aug. 20, 2022. The patent can be viewed on-line.

Dr. Terrance Owen, president and chief executive officer, states: "Issuance of the U.S. patent is an important achievement for Alda. Although we had previously been advised that the patent was supposed to be issued today, it is never certain until it is actually issued. Obviously, the United States is a very large market for Alda's products and the company can now move forward with this confidence that this component of its intellectual property protection is in place. This is an important asset to have in place and we are very pleased to have this important confirmation that this component of Alda's technology is novel and inventive."